Product Description
Its novel osteoarthritis drug, TG-C, is designed to conveniently and effectively treat osteoarthritis of the knee by reducing pain, increasing function and slowing the progression of the disease without the side effects usually seen with other palliative options such as NSAIDs or steroids.
Mechanisms of Action: Cell Therapy,TGFb
Novel Mechanism: Yes
Modality: Cell Therapy
Route of Administration: Injection
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Kolon Life Science
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: United States
Active Clinical Trial Count: 4
Highest Development Phases
Phase 3: Osteoarthritis
Phase 2: Osteoarthritis, Hip
Phase 1: Back Pain|Intervertebral Disc Degeneration|Spinal Diseases
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| TGC-DDD-101 | P1 |
Not yet recruiting |
Back Pain|Intervertebral Disc Degeneration|Spinal Diseases |
2027-11-01 |
43% |
| TGC-OAH-201 | P2 |
Not yet recruiting |
Osteoarthritis, Hip |
2025-10-01 |
24% |
| TGC-12301 | P3 |
Active, not recruiting |
Osteoarthritis |
2024-06-04 |
|
| TGC-15302 | P3 |
Active, not recruiting |
Osteoarthritis |
2024-03-06 |